Evidence map›Paper›PMID 37663120›Full record

ArticleJHEP reports : innovation in hepatology2023

Translating imaging traits of mass-forming intrahepatic cholangiocarcinoma into the clinic: From prognostic to therapeutic insights.

Gu-Wei Ji, Qing Xu, Chen-Yu Jiao, Ming Lu, Zheng-Gang Xu, Biao Zhang, Yue Yang, Ke Wang, Xiang-Cheng Li, Xue-Hao Wang

Open access · goldAbstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Gu-Wei JiHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China.
Qing XuDepartment of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China.
Chen-Yu JiaoHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China.
Ming LuDepartment of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China.
Zheng-Gang XuHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China.
Biao ZhangDepartment of General Surgery, Yancheng No.1 People's Hospital, Yancheng, PR China.
Yue YangDepartment of General Surgery, The First People's Hospital of Changzhou, Changzhou, PR China.
Ke WangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China.
Xiang-Cheng LiHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China.
Xue-Hao WangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNJiangsu Province Hospital · CNNantong University · CNThe First People's Hospital of Changzhou · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: The progress toward clinical translation of imaging biomarkers for mass-forming intrahepatic cholangiocarcinoma (MICC) is slower than anticipated. Questions remain on the biologic behaviour underlying imaging traits. We developed and validated imaging-based prognostic systems for resected MICCs with an appraisal of the tumour immune microenvironment (TIME) underpinning patient-specific imaging traits. Methods: Between January 2009 and December 2019, a total of 322 patients who underwent dynamic computed tomography/magnetic resonance imaging and curative-intent resection for MICC at three hepatobiliary institutions were retrospectively recruited, divided into training (n = 193) and validation (n = 129) datasets. Two radiological and clinical scoring (RACS) systems, one integrating preoperative variables and one integrating preoperative and postoperative variables, were developed using Cox regression analysis. We then prospectively analysed the TIME of tissue samples from 20 patients who met study criteria from January 2021 to December 2021 using multiplexed immunofluorescence. Results: Preoperative and postoperative MICC-RACS systems built on carbohydrate antigen 19-9, albumin, tumour number, radiological/pathological nodal status, pathological necrosis, and three radiological traits (arterial enhancement pattern, tumour boundary, and capsular retraction) demonstrated good performance in predicting disease-specific (C-statistic >0.80) and disease-free (C-statistic >0.75) survival that outperformed rival models and staging systems across study cohorts ( Conclusions: Our MICC-RACS systems are simple but powerful prognostic tools that may facilitate the understanding of spatially distinct TIMEs and patient-tailored immunotherapy approach. Impact and Implications: The progress toward clinical translation of imaging biomarkers for mass-forming intrahepatic cholangiocarcinoma (MICC) is slower than anticipated. Questions remain on the biologic behaviour of MICC underlying imaging traits. In this study, we proposed novel and easy-to-use tools, built on radiological and clinical features, that demonstrated good performance in predicting the prognosis either before or after surgery and outperformed rival models/systems across major imaging modalities. The characteristic radiological traits integrated into prognostic systems (arterial enhancement pattern, tumour boundary, and capsular retraction) were highly correlated with heterogeneous tumour-immune microenvironments, thereby renovating treatment paradigms for this difficult-to-treat disease.

Indexed as

Cancer prognosisIntrahepatic cholangiocarcinomaPrediction modelRadiological traitsTumour immune microenvironment

Identifiers

PMID37663120
PMCPMC10468367
OpenAlexW4383107286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.